Cargando…

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

BACKGROUND: Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during extended follow-up of the BIP trial in patients stratified by basel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arbel, Yaron, Klempfner, Robert, Erez, Aharon, Goldenberg, Ilan, Benzekry, Sagit, Shlomo, Nir, Fisman, Enrique Z., Tenenbaum, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722704/ https://www.ncbi.nlm.nih.gov/pubmed/26794137 http://dx.doi.org/10.1186/s12933-016-0332-6

Ejemplares similares

Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease
por: Younis, Arwa, et al.
Publicado: (2016)

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Impaired fasting glucose and left ventricular diastolic dysfunction in middle-age adults: a retrospective cross-sectional analysis of 2971 subjects
por: Milwidsky, Assi, et al.
Publicado: (2015)

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
por: Younis, Arwa, et al.
Publicado: (2017)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
por: Node, Koichi, et al.
Publicado: (2009)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery
por: Ram, Eilon, et al.
Publicado: (2020)

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Prognostic value of ejection fraction in patients admitted with acute coronary syndrome: A real world study
por: Perelshtein Brezinov, Olga, et al.
Publicado: (2017)

Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2017)

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Impaired Fasting Glucose Is the Major Determinant of the 20‐Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease
por: Younis, Arwa, et al.
Publicado: (2017)

Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation
por: Peled, Yael, et al.
Publicado: (2019)

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns
por: Shemesh, Joseph, et al.
Publicado: (2013)

Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy
por: Michowitz, Yoav, et al.
Publicado: (2019)

Heart Rate Variability for Risk Assessment of Myocardial Ischemia in Patients Without Known Coronary Artery Disease: The HRV‐DETECT (Heart Rate Variability for the Detection of Myocardial Ischemia) Study
por: Goldenberg, Ilan, et al.
Publicado: (2019)

Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation
por: Ram, Eilon, et al.
Publicado: (2019)

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry
por: Steiner, Hillel, et al.
Publicado: (2016)

Precipitating Factors for Acute Heart Failure Hospitalization and Long-Term Survival
por: Berkovitch, Anat, et al.
Publicado: (2015)

Revascularization outcomes in diabetic patients presenting with acute coronary syndrome with non-ST elevation
por: Ram, Eilon, et al.
Publicado: (2022)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
por: Kogan, Alexander, et al.
Publicado: (2018)

Ethnic Disparity in Mortality Among Ischemic Heart Disease Patients. A-20 Years Outcome Study From Israel
por: Abu-Much, Arsalan, et al.
Publicado: (2021)

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
por: Teramoto, Tamio, et al.
Publicado: (2012)

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?
por: Fisman, Enrique Z, et al.
Publicado: (2014)

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study
por: Ohno, Yuko, et al.
Publicado: (2014)

Cessation of Bezafibrate in patients with chronic kidney disease improves renal function
por: Zingerman, Boris, et al.
Publicado: (2020)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Angioscopic Evaluation of Stabilizing Effects of Bezafibrate on Coronary Plaques in Patients With Coronary Artery Disease
por: Uchida, Yasumi, et al.
Publicado: (2000)

Clinical impact of diabetes mellitus in patients undergoing transcatheter aortic valve replacement
por: Berkovitch, Anat, et al.
Publicado: (2015)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
por: Leibovitz, Eyal, et al.
Publicado: (2013)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Type 2 diabetes mellitus increases long-term mortality risk after isolated surgical aortic valve replacement
por: Ram, Eilon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5e2k5lnq5k8mlcojd5aol2cstd